Cargando…

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma

Detalles Bibliográficos
Autores principales:	Hao, M, Franqui-Machin, R, Xu, H, Shaughnessy, J, Barlogie, B, Roodman, D, Quelle, D E, Janz, S, Tomasson, M H, Sanderson, R D, Qiu, L, Frech, I, Tricot, G, Zhan, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508075/ https://www.ncbi.nlm.nih.gov/pubmed/28400617 http://dx.doi.org/10.1038/leu.2017.115

Ejemplares similares

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

Role of NEK2A in Human Cancer and Its Therapeutic Potentials
por: Xia, Jiliang, et al.
Publicado: (2015)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Heparanase Regulates Levels of Syndecan-1 in the Nucleus
por: Chen, Ligong, et al.
Publicado: (2009)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
por: Jung, O, et al.
Publicado: (2016)

Forty Years of Basic and Translational Heparanase Research
por: Vlodavsky, Israel, et al.
Publicado: (2020)

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells
por: Li, Juan, et al.
Publicado: (2016)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
por: Gu, Zhimin, et al.
Publicado: (2014)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Osteoclasts are essential for TNF-mediated joint destruction
por: Redlich, KR, et al.
Publicado: (2002)

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells
por: Suvannasankha, Attaya, et al.
Publicado: (2015)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment
por: Lischer, Christopher, et al.
Publicado: (2023)

Heparanase—A single protein with multiple enzymatic and nonenzymatic functions
por: Vlodavsky, Israel, et al.
Publicado: (2023)

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017)

Heparanase and the hallmarks of cancer
por: Jayatilleke, Krishnath M., et al.
Publicado: (2020)

Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function
por: Amin, Rada, et al.
Publicado: (2020)

NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma
por: Xia, Jiliang, et al.
Publicado: (2020)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
por: Delgado-Calle, Jesus, et al.
Publicado: (2019)

Kinase Inhibitor Profile for Human Nek1, Nek6, and Nek7 and Analysis of the Structural Basis for Inhibitor Specificity
por: Moraes, Eduardo Cruz, et al.
Publicado: (2015)

High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression
por: Qing, Qing, et al.
Publicado: (2015)

Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma
por: Feng, Xiangling, et al.
Publicado: (2022)

Up to your NEK2 in CIN
por: Seachrist, Darcie D., et al.
Publicado: (2021)

Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression
por: Dib, Amel, et al.
Publicado: (2006)

Heparanase and Autoimmune Diabetes
por: Simeonovic, Charmaine J., et al.
Publicado: (2013)

Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone
por: Pennisi, Angela, et al.
Publicado: (2010)

The role of dendritic cells derived osteoclasts in bone destruction diseases
por: Wang, Bo, et al.
Publicado: (2020)

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
por: Sabol, Hayley M., et al.
Publicado: (2022)

Blocking the ZZ Domain of Sequestosome1/p62 Suppresses Myeloma Growth and Osteoclast Formation In Vitro and Induces Dramatic Bone Formation in Myeloma-Bearing Bones In Vivo
por: Teramachi, Jumpei, et al.
Publicado: (2015)

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis
por: Brenne, Anne-Tove, et al.
Publicado: (2009)

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
por: Guo, Wancheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eril5lb7mp7piflbetm3l68m8s